Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Coagulation factor II (thrombin) receptor-like 3 (F2RL3) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. Additionally we are shipping F2RL3 Kits (27) and F2RL3 Proteins (5) and many more products for this protein.
Showing 10 out of 109 products:
Human Monoclonal F2RL3 Primary Antibody for ELISA, WB - ABIN396605
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 5 references for ABIN396605
Human Polyclonal F2RL3 Primary Antibody for WB - ABIN2801951
Kahn, Hammes, Botka, Coughlin: Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. in The Journal of biological chemistry 1998
Show all 4 references for ABIN2801951
Human Monoclonal F2RL3 Primary Antibody for IHC, ELISA - ABIN1724706
Xie, Guo: Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation on the plasma membrane. in The Journal of biological chemistry 2004
Show all 4 references for ABIN1724706
Human Polyclonal F2RL3 Primary Antibody for IF (p), IHC (p) - ABIN673224
Oláh, Kálmán, Tóth, Zvara, Sántha, Ivitz, Janka, Pákáski: Proteomic Analysis of Cerebrospinal Fluid in Alzheimer's Disease: Wanted Dead or Alive. in Journal of Alzheimer's disease : JAD 2014
Human Polyclonal F2RL3 Primary Antibody for ICC, FACS - ABIN1742018
Ossovskaya, Bunnett: Protease-activated receptors: contribution to physiology and disease. in Physiological reviews 2004
Human Polyclonal F2RL3 Primary Antibody for ELISA, WB - ABIN1536156
Kahn, Zheng, Huang, Bigornia, Zeng, Moff, Farese, Tam, Coughlin: A dual thrombin receptor system for platelet activation. in Nature 1998
Human Monoclonal F2RL3 Primary Antibody for ELISA, WB - ABIN563904
Muehlschlegel, Perry, Liu, Fox, Smith, Lichtner, Collard, Shernan, Hartwig, Body, Hoffmeister: Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. in American journal of hematology 2013
Suppression of PAR4 (show PAWR Antibodies) expression has no significant effect on the proliferation of SW620 cells, but can inhibit the migration of the cells.
Both GPIbalpha (show GP1BA Antibodies) and PAR4 (show PAWR Antibodies) are required for thrombin (show F2 Antibodies)-induced reactive oxygen species formation in human platelets.
Bladder PAR (show JTB Antibodies) activation elicits urothelial MIF (show AMH Antibodies) release and urothelial MIF (show AMH Antibodies) receptor signaling at least partly through CXCR4 (show CXCR4 Antibodies) to result in abdominal hypersensitivity without overt bladder inflammation
protease-activated receptor 4 and Trefoil factor 2 (show TFF2 Antibodies) are expressed in human colorectal cancer
The PAR4 (show PAWR Antibodies) expression and activation via intracellular signaling pathways and the role of PAR4 (show PAWR Antibodies) signaling pathways in the development and maintenance of pain.
This review summarizes the roles of PAR4 (show PAWR Antibodies) in coagulation and other extracellular protease pathways.
Findings suggested that F2RL3 methylation is a very strong predictor of lung cancer risk and mortality, particularly at older age.
Lower F2RL3 methylation is a strong predictor of mortality, including all-cause, cardiovascular, cancer and other mortality. Systemic adverse effects of smoking may be mediated by pathways associated with F2RL3 methylation.
exosite II is critical for activation of PAR4 (show PAWR Antibodies).
provide evidence against the hypothesis that PAR-1 (show MARK2 Antibodies) and PAR-4 (show PAWR Antibodies) stimulation of platelets trigger differential release of alpha-granules
The lack of LKB1 (show STK11 Antibodies) in skeletal muscle leads to an increased inflammatory state.
Partial deficiency of cardiac LKB1 (show STK11 Antibodies) promotes the adverse effects of a high-fat, high-sucrose diet on the myocardium, leading to worsening of diastolic function and the de novo appearance of systolic dysfunction.
Rapid activation of AMPK (show PRKAA1 Antibodies) was detected after exposure of cortical neuronal cultures to zinc, which was induced by LKB1 (show STK11 Antibodies) activation but not increased intracellular AMP (show TMPRSS5 Antibodies) levels or CaMKKbeta activation.
Par4 deficiency offers cardioprotection after acute ischemia reperfusion injury.
We proposed that LKB1 (show STK11 Antibodies) regulates cerebellar development by controlling GCPs proliferation through Shh (show SHH Antibodies) signalling during cerebellar development.
LKB1 (show STK11 Antibodies) deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.
Bladder PAR4 stimulation affected urothelial HMGB1 (show HMGB1 Antibodies) release.
LKB1 (show STK11 Antibodies) promotes maturation of bile ducts during biliary morphogenesis.LKB1 and Notch (show NOTCH1 Antibodies) share a common genetic program in the liver, and regulate bile duct morphogenesis.
STK11/LKB1 (show STK11 Antibodies)-inactivating mutations were associated with reduced expression of PD-1 (show PDCD1 Antibodies) ligand PD-L1 (show CD274 Antibodies) in mouse and patient tumors as well as in tumor-derived cell lines.
activation of AKT (show AKT1 Antibodies) and mTORC1, the double knockout of PTEN (show PTEN Antibodies) and LKB1 (show STK11 Antibodies) contributes to distinct cell-specific aspects of tumor development and progression.
Coagulation factor II (thrombin) receptor-like 3 (F2RL3) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. F2RL3 is also a member of the protease-activated receptor family. F2RL3 is activated by proteolytic cleavage of its extracellular amino terminus. The new amino terminus functions as a tethered ligand and activates the receptor. F2RL3 is activated by thrombin and trypsin.
proteinase-activated receptor 4
, coagulation factor II (thrombin) receptor-like 3
, coagulation factor II (thrombin)
, protease-activated receptor-4
, thrombin receptor-like 3
, coagulation factor II receptor-like 3
, protease-activated receptor 4
, LKB1 short isoform
, liver kinase B1 homolog
, serine/threonine-protein kinase 11
, serine/threonine-protein kinase LKB1
, serine/threonine-protein kinase STK11